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Abstract: Many bioconjugation strategies for DNA oligonu-
cleotides and antibodies suffer limitations, such as site-
specificity, stoichiometry and hydrolytic instability of the
conjugates, which makes them unsuitable for biological
applications. Here, we report a new platform for the prepara-
tion of DNA-antibody bioconjugates with a simple benzoyla-
crylic acid pentafluorophenyl ester reagent. Benzoylacrylic-
labelled oligonucleotides prepared with this reagent can be site-
specifically conjugated to a range of proteins and antibodies
through accessible cysteine residues. The homogeneity of the
prepared DNA-antibody bioconjugates was confirmed by
a new LC-MS protocol and the bioconjugate probes were
used in fluorescence or super-resolution microscopy cell
imaging experiments. This work demonstrates the versatility
and robustness of our bioconjugation protocol that gives site-
specific, well-defined and plasma-stable DNA-antibody bio-
conjugates for biological applications.
Introduction
Cross-linking of various types of molecules leading to
chimeric constructs with combined functionalities has been
gaining attention across the fields of chemical biology,
biotechnology, and medicine.[1] Among these, proteins are
one of the most important and valuable class of biomolecules
owing to the wide range of functions they fulfil in living
organisms. Numerous studies have been undertaken to extend
the diversity of protein functionalities by introducing non-
natural labels or “tags” in the emerging field of chemical
protein modification.[1a] Besides proteins, nucleic acids (NAs)
are also an extensively studied class of biomolecules. It is
mainly the highly specific and predictable base pairing that
makes DNA or RNA oligonucleotides (ONs) unique tools for
the design of biomolecular hybrids with new structures and
improved functions. ONs have been applied in the design of
DNA-microarrays,[2] other nanostructures,[3] imaging[4] and as
therapeutic agents.[5] By joining proteins and NAs in a single
biomolecular scaffold, NA-protein hybrids can combine the
programmable sequence recognition properties of NAs and
diverse functionalities of proteins. Two major research areas
that benefit from the dual functionality of NA-protein
bioconjugate constructs are bioanalysis and nanofabrica-
tion.[6] In addition, conjugation of ONs to antibodies has
been used for the antibody-mediated delivery of therapeutic
ONs,[7] cytotoxic agents through intercalation[8] or hybrid-
ization of complementary DNA ONs,[9] decoration of DNA
nanostructures with multiple proteins[10] and fluorophores[11]
and DNA-antibody bioconjugates have been used as probes
for super-resolution imaging by means of the DNA-PAINT
method.[12]
However, for constructs like DNA-antibody conjugates to
become viable for bioanalytical and biological applications,
efficient methods for their production are needed. Many
different chemical approaches are available to prepare these
bioconjugates.[13] The choice of conjugation method usually
depends on the scaffold of the protein of interest, and the
main challenges are scalability, control over efficacy, site-
specificity and stoichiometry of the NA bioconjugation.
Strategies for the preparation of covalent DNA-antibody
conjugates can be divided into two main categories: 1)
approaches based on proteins modified with functional
groups suitable for biorthogonal reactions, such as strain-
promoted azide–alkyne cycloaddition[14] or inverse electron-
demand Diels–Alder reactions[14c,15] (Figure 1 a) or 2) direct
conjugation of modified ONs to native proteins by using
bifunctional cross-linkers (Figure 1b).[16] Whereas the former
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requires either genetic manipulation of the protein of interest
or additional steps to introduce the functional groups for the
biorthogonal ligation, the latter cross-links the reactive amino
acid residues on the protein surface with modified ONs
directly. However, proteins usually contain multiple reactive
residues, which often results in nonspecific labelling at sites
important for protein activity and/or binding. To avoid
formation of inactive conjugates, site-specific bioconjugation
of NAs to proteins with control over modification site is
required; often attempted by using bifunctional cross-linkers.
Functionalized homo- or hetero-bifunctional linkers usually
contain reactive activated esters for amine modification or
Michael acceptor moieties for conjugation of thiol bearing
molecules (Figure 1c). N-hydroxysuccinimide (NHS) ester
and maleimide moieties are some of the most frequently used
scaffolds but various other crosslinkers are available.[16]
Although popular, bifunctional linkers based on NHS and
maleimide functionalities have some drawbacks. Maleimide is
widely used for reactions with thiol-containing molecules but
the selectivity of maleimide towards thiols highly depends on
the reaction pH. At neutral pH, thiols react with maleimide
1000-times faster than amines but at higher pH reaction with
amine is favored.[17] This non-specific labelling can lead to
mixtures of heterogenous conjugates with various character-
istics. Furthermore, at more alkaline pH, hydrolysis of both
the NHS ester and maleimide occurs, which results in an
unreactive carboxylic acid and maleamic acid, respectively.[16]
Another disadvantage of the maleimide reagents is the
limited stability of the formed thioether bond, which can
undergo a rapid thiol-exchange reaction.[17,18] To avoid some
of the downsides of these reagents, improved conjugation
techniques that give site-specific, homogenous and well-
defined DNA-antibody conjugates are desired. In this work,
we report a strategy that leads to chemically
defined constructs by employing new benzoyla-
crylic acid pentafluorophenyl ester (BA-PFP)
labelling reagent 2 (Figure 1d) as an alternative
to the cross-linking of ONs and proteins by
conventional maleimide-NHS ester-based re-
agents. Importantly, we use the DNA-antibody
conjugates generated as probes in fluorescence
microscopy and super-resolution DNA-PAINT
imaging experiments.
Results and Discussion
Our approach towards the preparation of
DNA-antibody conjugates was based on the meth-
od for cysteine protein modification using benzoy-
lacrylic (BA) reagents recently developed in our
laboratory.[19] With these reagents (sometimes in
stoichiometric amounts) proteins with solvent-
accessible cysteine residues are irreversibly modi-
fied with reaction kinetics comparable to malei-
mide chemistry.[19a] This approach offers site-spe-
cific, stable constructs that overcome the disadvan-
tages of maleimide bioconjugates, such as hydro-
lytic instability of reagents and problems with
retro-Michael addition reaction.[19a] To introduce the BA
moiety to DNA ONs, we used bifunctional reagent 2, which is
easily prepared by activation of commercially available trans-
3-benzoylacrylic acid (1) (see Organic synthesis of BA
reagents in the SI). PFP-activating ester group was chosen
for its known higher hydrolytic stability over NHS-ester
derivatives.[16] Bifunctional reagent 2 can be stored as a solid
for months or in solution for weeks and used without any
significant loss of the reactivity for the modification of various
amino group-containing small molecules or biomolecules (see
Organic synthesis of BA reagents in the SI).
A small optimization of the DNA-labelling reaction was
performed on the commercially available short single-strand-
ed (ss) DNA ON 5’-NH2-ss11-mer that contains 11 nucleo-
tides and a 5’-amino modifier (see 5’-NH2 DNA ON BA-
labelling reaction optimization in the SI). Conditions that
used different amounts of reagent and dimethyl formamide
(DMF) were screened. The best results were obtained with
100 equiv of 2 in 20% DMF in phosphate (NaPi) buffer at
pH 8.0 and 37 8C overnight (Table S1). Under these condi-
tions, complete conversion of the starting ON into BA-
labelled ON (determined by LC-MS) was obtained. Lower
amounts of linker and shorter reaction times did not lead to
complete conversions and more DMF or linker resulted in
a small fraction (< 10%) of the second DNA modification,
probably on one of the nucleophilic sites on nucleobases,
being detected. The second DNA modification was also noted
after prolonged reaction times (> 48 h) and under more basic
conditions (NaPi pH 10.0 buffer for 24 h). Labelling of amino-
modified DNA ONs by 2 can be efficiently performed on
different reaction scales (20 mL–1 mL) and at a range of ON
concentrations (25–100 mM). BA-labelled ONs can be easily
Figure 1. Strategies for the preparation of covalent NA-protein bioconjugates.
a) Conjugation strategy based on the introduction of handles for bioorthogonal
ligation reactions. b) Conjugation of ONs and native proteins by heterobifunctional
linkers. c) Examples of heterobifunctional linkers bearing various spacers common-
ly used for the DNA-protein bioconjugation. d) Conjugation method with novel BA-
PFP reagent 2 described in this work.
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purified by using size-exclusion spin columns for small-scale
preparations or RP-HPLC for larger-scale labelling reactions.
The optimized labelling conditions were used to label four
amino-modified ONs, 5’-NH2-ss11-mer, 5’-NH2-ss25-mer, 5’-
NH2-ss50-mer with different lengths, including double-
stranded (ds) DNA-ON 5’-NH2-ds19-mer (Figure 2). We
chose examples of modified ONs based on their possible
applications: shorter (ss11-mer) ONs are usually used in
preparation of probes for super-resolution microscopy by
DNA-PAINT,[12] whereas longer ones are in the range of sizes
used for therapeutic[7] (ss25-mer or ds19-mer) or biomedical[3]
(ss50-mer) applications. All BA-labelled ONs were success-
fully characterized by LC-MS (Figure 2b) and in all cases,
complete conversion of the starting material into expected
product was observed. It is necessary to mention that for
modification of 5’-NH2-ss50-mer more linker 2 (200 equiv
instead of 100 equiv) was needed to ensure complete con-
version of the starting ON (Figure S22).
In a similar manner, 5’-NH2-ss11-mer and 5’-NH2-ss25-
mer ONs were modified with commercially available 3-
(maleimido)propionic acid N-hydroxysuccinimide ester 5
using the optimized BA labelling conditions stated above.
Complete conversion of the starting material to either the
maleimide (minor) or hydrolyzed maleamic acid (major)
labelled product was observed by LC-MS for both reactions
(Figures S25 and S26). RMss11 (1:9 5’-maleimide-ss11-
mer:5’-maleamic acid-ss11-mer) was then incubated at 37 8C
to test hydrolytic stability of the maleimide-labelled ON.
After 24 h, complete hydrolysis of 5’-maleimide-ss11-mer to
5’-maleamic acid-ss11-mer (Figure S27) was obtained. In
comparison, no hydrolysis of 5’-BA-ss11-mer was observed
under the same conditions (Figure S29), highlighting the
remarkable hydrolytic stability of the BA-labelled ONs.
With a well-working protocol for the label-
ling of amino-modified ONs, we wanted to
proceed with the bioconjugation of BA-la-
belled ONs to proteins and antibodies. Be-
cause we were interested in developing a pro-
tocol for the generation of site-specific and
stoichiometric (1:1) DNA-protein conjugates,
we investigated an analytical method for the
precise characterization of these constructs.
Bioconjugation reactions between ONs and
proteins are typically analyzed by gel electro-
phoresis under reducing or non-reducing con-
ditions.[7a, 20] Although this analytical method is
useful to confirm successful bioconjugation
reaction has taken place, its accuracy and
resolution is inferior to results obtained by
mass spectrometry (MS), which is nowadays
the prevailing analytical tool for structural
characterization of bioconjugates. Accuracy of
characterization is needed for applications that
require use of well-defined and homogenous
conjugates, for example development of im-
proved therapies[21] or single-molecule tech-
niques in biophysics.[22] One of the earliest
examples of DNA-protein hybrids character-
ization by MS involved bioconjugates that
were enzymatically pre-digested and then analyzed by LC-
MS/MS.[23] Besides this, only a handful of reports on the
characterization of DNA-protein bioconjugates by MS meth-
ods have been published. These include use of matrix-assisted
laser desorption/ionization MS that usually requires specific
sample and matrix preparation.[24] Electrospray ionization
(ESI) MS was used to characterize NA-protein conjugates but
gave low mass accuracy and errors in mass ranges of tens of
Da.[7b, 25] Since MS provides more precise results than gel
electrophoresis, we believed that a liquid chromatography-
mass spectrometry (LC-MS) method for the accurate char-
acterization of DNA-protein bioconjugates could be devel-
oped. Analysis by LC-MS is well-established for the accurate
characterization of bioconjugates with small molecules, how-
ever, its use for the analysis of DNA-protein conjugates is not
that straightforward. To the best of our knowledge a simple,
accurate, reproducible and reliable LC-MS method for
routine characterization of intact DNA-protein hybrids has
not been reported.
Bioconjugate 594Nup98 G85C-ss11-mer was chosen as
a model for the optimization of the LC-MS method. The
conjugate was prepared by reaction of a short BA-labelled
ON 5’-BA-ss11-mer with the single-domain antibody against
Xenopus nucleoporin complex 594Nup98 G85C[26] bearing
a single available cysteine residue (Figure 3a). Complete
conversion of the starting protein was obtained under mild
reaction conditions (pH 8.0, 25 8C, 2 equiv of the BA-labelled
ON; Figure S30). At first, this bioconjugation reaction was
analyzed by standard LC-MS conditions suitable for proteins
with formic acid as the LC-MS additive (Figure 3b). Under
these conditions, ion series with multiple ion species was
obtained, which was deconvoluted by the MaxEnt1 algorithm
and led to a peak with a molecular weight that corresponded
Figure 2. Modification of 5’-amino DNA ONs and LC-MS characterization of BA-
labelled products. Deconvoluted mass spectra show peaks with masses expected for
ss11-mer, ss25-mer, ss50-mer and ds19-mer 5’-BA-labelled products. Extra peaks (as
indicated by black arrows) seen with longer ONs (ss25-mer and ss50-mer) correspond
to hexaflufluroisopropanol adducts (+168 Da) formed during electrospray ionization.
For full LC-MS spectra see Figures S20–S23.
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to the expected product (ca. 17.5 kDa). This was observed
together with other ions with higher masses (Figure 3 b),
which were assigned to ion species with different levels of
saturation with counter cations, such as Na+ and K+ on the
phosphate backbone of the ON part of the bioconjugate. We
assumed that this was due to the phosphate buffer used in the
labelling reaction or the mobile phase used for the LC-MS
analysis. So, to eliminate these species, we tested whether
a different LC-MS mobile phase additive would provide
better results. With ammonium acetate[27] at 10 mM concen-
tration, much cleaner extracted ion series were obtained
relative to experiments that used formic acid as the LC-MS
additive (Figure 3b) and deconvolution led to a single peak
with the mass corresponding to the calculated mass of the
desired conjugate (17516 Da). This was probably due to the
saturation of the ON phosphate backbone by volatile
ammonium counter cations and overall stabilization of the
charge of the DNA-protein conjugate sample. An ion series of
an individual species could be then extracted and deconvo-
luted into a mass spectrum that contained a single peak for
the expected product. Concentration of LC-MS additive had
little effect on the signal of the extracted ion
series or deconvoluted mass spectra at higher
(10 mM) or lower (5 mM, 2 mM or 1 mM)
ammonium acetate concentrations (Figures S32–
S35). However, the use of higher concentrations
was noticeable in the UV trace of the LC whereby
background noise was detected. To examine the
impact of the counter anion of the LC-MS
additive on the analysis, 10 mM ammonium
formate was also tested. We observed a clear
effect on the ionization of the sample, but the
deconvolution and reconstruction of the total
mass ion gave a similar result as with 10 mM
ammonium acetate (Figure 3b). At 1 mM con-
centration, extracted ion series clearly show
differences in the presence and intensity of ion
species, which we attributed to the less efficient
ionization by ammonium formate at lower con-
centration (Figure S36). Based on all these ob-
servations, we chose 1–10 mM ammonium ace-
tate as the LC-MS additive for the accurate
analysis and characterization of our DNA-anti-
body conjugates. We then tested the applicability
and accuracy of our LC-MS method for the
characterization of 11-mer conjugates with other
variants of Xenopus nucleoporin nanobodies.[26]
Constructs 576Nup98 A75C-ss11-mer, 427Nup93
C4-ss11-mer and 443Nup98 C4-ss11-mer were
prepared similarly to 594Nup98 G85C-ss11-mer
conjugate (Figures S38–S40). In all the cases, our
optimized LC-MS method gave accurate results
for the deconvoluted mass spectra of prepared
conjugates with observed masses in the range of
 5 Da from calculated values (Figure 3c). The
advantages of site-specificity and reproducibility
of the conjugation reaction combined with the
accuracy of our LC-MS analysis could allow
application for the construction of well-defined,
functionally active DNA-protein conjugates.
Having optimized the conditions for the LC-MS analysis
and characterization of the DNA-antibody conjugates, we
wanted to explore the applicability of our bioconjugation
protocol to proteins of various sizes with cysteine residues
with different accessibility and reactivity. We managed to
successfully conjugate 5’-BA-ss11-mer to four different pro-
teins including Ubiquitin K63C (with an engineered cysteine
residue),[28] C2A domain of Synaptotagmin-I C2Am-C95
(derivatives of which are used as probes for in vivo imaging
of apoptosis),[29] Annexin V-C315[30] and an recombinant
human serum albumin-Recombumin (Albumedix Ltd) HSA-
C34[31] (which often serves as a versatile carrier for therapeu-
tic and diagnostic agents). In all cases, bioconjugation
conditions were optimized to obtain complete conversion of
the starting protein into desired bioconjugate with no more
than 10 equiv of BA-labelled ON used (Figure 4a). All
reactions were performed in 50 mM NaPi buffer at pH 8.0,
25 8C, 30 min or 1 h to obtain UbK63C-ss11-mer, C2Am-C95-
ss11-mer and HSA-C34-ss11-mer conjugates (Figure 4b).
Annexin V-315-ss11-mer conjugate required a reaction tem-
Figure 3. Optimization of the LC-MS method for the characterization of the model
DNA-antibody conjugate. a) Conditions used for the preparation of anti-nucleoporin
nanobody conjugates with a short ss11-mer DNA ON. b) Comparison of the effect
of different LC mobile phase additives on the ion series and deconvoluted mass
spectra for conjugate 594Nup98 G85C-ss11-mer. c) LC-MS characterization of
prepared ss11-mer conjugates of different anti-nucleoporin nanobody variants with
deconvoluted mass spectra and masses that correspond to expected products. For
full LC-MS spectra see Figures S30–S40.
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perature of 37 8C and a prolonged reaction time because of
the more buried and consequently less reactive Cys-315
residue (Figure S44). Moreover, by conjugating longer ssONs
5’-BA-ss25-mer, 5’-BA-ss50-mer and even dsON 5’-BA-ds19-
mer to C2Am-C95 (Figure 4c) we have shown that our DNA-
protein bioconjugation protocol is versatile and suitable for
conjugation of different types of BA-labelled ONs. As
a control experiment, we mixed Ubiquitin K63C with an
unmodified 5’-NH2-ss11-mer (Figure S42). Formation of
conjugate was not observed under these conditions, which
demonstrates that unspecific bioconjugation reactions do not
occur in the absence of the BA moiety. All the prepared
DNA-protein bioconjugates were successfully characterized
by our optimized LC-MS method thus proving its reliability
and accuracy in the analysis of DNA-protein constructs for
a wide range of masses and types of bioconjugates.
Next, we extended our DNA biocon-
jugation method to antibodies. Site-spe-
cific and stoichiometric conjugation of
DNA or RNA ONs to monoclonal anti-
bodies (mAbs) or antibody fragments is
desired for applications like structural
DNA nanotechnology and imaging,[32]
preparation of well-defined DNA-anti-
body nanostructures[33] or delivery of
therapeutic ONs, such as antisense ONs
(AOs)[7a] or small-interfering RNAs
(siRNAs).[7b] As only a limited number
of bioconjugation methods for such
constructs are available, we wanted to
test the reliability of our method in the
preparation of ON-antibody conjugates.
With our bioconjugation platform, light
(LC) and heavy chain (HC) subunits of
immunoglobulin G (IgG) mAbs can be
easily modified with BA-labelled ONs
via engineered cysteine residues. To
demonstrate this we used Thiomab LC-
V205C,[34] a mAb targeting the human
epidermal growth factor receptor 2
(HER2) that is over-expressed on the
cell surface of certain types of breast
cancer, and Gemtuzumab mAb variants,
which recognize the myeloid differentia-
tion antigen CD33 on acute myeloid
leukemia (AML) cells.[35] By using our
bioconjugation protocol, cysteine resi-
dues on LCs of Thiomab LC-V205C and
Gemtuzumab LC-V205C and cysteine
residues on HCs of Gemtuzumab i239C
and Gemtuzumab HC-S442C were the
only amino acid residues modified with
5’-BA-ss11-mer ON (Figure 4d). For the
bioconjugation reaction conditions we
used 5 equiv of the BA-labelled ON per
cysteine residue in 50 mM NaPi buffer at
pH 8.0 and 37 8C for 1 h, which led in all
cases to complete conversion of starting
antibody materials into desired biocon-
jugates. To rule out any chemoselectivity issues, 5’-BA-ss11-
mer was also reacted with Trastuzumab, a HER2 targeting
mAb containing no additional accessible cysteine residues.
LC-MS analysis revealed no modification in the light or heavy
chain after 1 h at 37 8C (identical results were obtained when
leaving the reaction for 48 h; Figure S53), demonstrating the
site-specificity of the BA-labelled ON reagents towards
cysteine residues. It is worth noting that LC-MS analysis on
ON-modified HC antibody fragments was challenging. As
seen in Figure 4d (see also Figures S51 and S52), the signal of
the main peak in the deconvoluted mass spectra of HCs of the
ss11-mer-modified Gemtuzumab i239C and Gemtuzumab
HC-S442C variants is of lower intensity and accompanied by
other peaks. Although with a slightly larger error, observed
peaks are in the range of expected masses for bioconjugate
products, which suggests the DNA-antibody conjugation
Figure 4. Site-specific NA-antibody conjugates. a) Scope of the conjugation of BA-modified
ONs through cysteine residues to proteins and antibodies of various sizes and formats.
b) Deconvoluted mass spectra obtained from the modification of four model proteins with the
5’-BA-ss11-mer ON. c) Deconvoluted mass spectra obtained from the modification of C2Am-
C95 with different BA-modified ONs. d) Deconvoluted mass spectra of prepared DNA-antibody
conjugates that bear antibodies against HER2 or CD33 receptors. To observe individual LC and
HC of IgG mAbs, disulfide bonds between LCs and HCs were reduced prior to LC-MS analysis
(SI). e) Deconvoluted mass spectra of four different 2Rb17c-C138 conjugates. Each DNA-
protein bioconjugation reaction was performed under the optimized conditions (SI) at least
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reaction was successful. The inaccuracy in the LC-MS analysis
for this type of conjugate could be attributed to their
inefficient ionization caused by glycosylation of mAb with
various glycans attached to HCs.[36]
In addition to full-length IgG mAbs, we have applied our
DNA-protein bioconjugation protocol to single domain anti-
HER2 antibody 2Rb17c-C138[37] with all four prepared BA-
labelled ONs (Figure 4 e). Here, complete conversion was
observed and all products were characterized by LC-MS with
masses as expected. The range of BA-labelled ONs of various
lengths successfully conjugated to an array of various proteins
and antibodies clearly demonstrates the versatility of this
simple and powerful, bioconjugation method to give site-
specific and stoichiometric DNA-protein conjugates. 2Rb17c-
C138 was also reacted with RMss11 (1:9 5’-maleimide-ss11-
mer:5’-maleamic acid-ss11-mer) under the same conditions as
those used for 5’-BA-ss11-mer. Only ca. 64 % conversion of
the starting material to the desired conjugate was observed
(Figure S55). As a control, 2Rb17c-C138 was also reacted
with 5’-maleamic acid-ss11-mer and as expected, formation of
conjugate did not occur (Figure S28). The low conversion of
2Rb17c-138 to 2Rb17cc-C138-ss11-mer using RMss11 can be
attributed to the high percentage of 5’-maleamic acid-ss11-
mer present in the reaction mixture. Altogether, the results of
both antibody bioconjugation and ON labelling experiments
confirm the superior performance of the BA functionality
over maleimides in DNA-antibody bioconjugation reactions.
As we were keen to develop a bioconjugation method
which provides DNA-antibody conjugates suitable for in vivo
studies, we assessed the plasma stability of 2Rb17c-C138-ss11-
mer. The conjugate was added to 10% human plasma in PBS
buffer pH 7.4 at 37 8C, and samples were taken at four
different time points (0 h, 24 h, 48 h and 72 h) and analyzed by
LC-MS (Figure 5a). No decomposition of 2Rb17c-C138-ss11-
mer was seen, which strongly suggests that it is stable in the
presence of human plasma and opens up opportunities for this
method to be used for the preparation of hybrid biomolecular
constructs for in vivo applications, such as improved targeted
cancer therapy by antibody-mediated delivery of siRNA,
antisense ONs or other therapeutic ONs.[38]
Ultimately, Thiomab LC-V205C-ss11-mer and 2Rb17c-
C138-ss11-mer conjugates were used as probes in super-
resolution microscopy ex-
periments with the DNA-
PAINT method.[12, 14b,24c]
The sequence of the conju-
gated ON,[39] called “dock-
ing strand”, is designed to
be complementary to an-
other short 10-mer fluoro-
phore-labelled DNA ON,
referred to as “imager
strand”. The low melting
temperature of the corre-
sponding duplex causes the
“imager strand” to repeat-
edly bind and dissociate
from the target “docking
strand” and this transient
binding enables to locate
“docking strand”-labelled
antibody. The detected
“blinking” is then used to
reconstruct the super-reso-
lution image. Both Thio-
mab LC-V205C full-length
IgG and 2Rb17c-C138 sin-
gle-domain antibody selec-
tively bind to HER2 recep-
tors on breast cancer cells,
so we investigated whether
HER2 receptor binding of
both bioconjugate probes





breast cancer cells (see
DNA-PAINT imaging ex-
Figure 5. Bioconjugate integrity studies and cell imaging experiments. a) LC-MS based conjugate integrity
study of the anti-HER2 nanobody conjugate 2Rb17c-C138-ss11-mer in the presence of 10 % human plasma
with deconvoluted mass spectra of samples taken at specified time points. No detectable degradation of the
DNA-nanobody conjugate was observed and an intact 2Rb17c-C138-ss11-mer conjugate was identified by LC-
MS after 72 h. For full LC-MS spectra see Figures S60–S63. b) Super-resolution images of HER2 receptors on
SKBR3 breast cancer cells obtained by DNA-PAINT method. 2Rb17c-C138-ss11-mer and Thiomab LC-V205C-
ss11-mer were used as probes. Scale bars represent 1000 nm (top images) or 500 nm (bottom images).
c) Epifluorescence microscopy imaging of the HER2 receptor-mediated internalization of the 2Rb17c-C138-
Cy3-3’-ss25-mer conjugate on SKBR3 breast cancer cells. Obtained images of SKBR3 cells incubated for 2 h:
without any probe, with 2Rb17c-C138 antibody, 5’-NH2-Cy3-3’-ss25-mer ON, 2Rb17c-C138-Cy3-3’-ss25-mer or
with 2Rb17c-C138-Cy3-3’-ss25-mer after 1 h incubation with Trastuzumab. Images were processed using
ImageJ software, scale bars represent 100 mm. Experiments were performed two independent times.
Representative data from one experiment is shown. For full experimental details see SI.
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periments in the SI) which are known for their high HER2
receptor expression levels.[40] High localization numbers were
detected in both cases and super-resolution images of HER2
receptor networks on the surface of SKBR3 cells were
acquired (Figure 5 b). Results obtained from these experi-
ments confirm that both prepared DNA-antibody conjugates
retained their target receptor binding activity.
To provide further insight into intracellular trafficking and
localization of generated bioconjugates, another experiment
which provides qualitative evidence on the receptor-mediated
internalization of the DNA-antibody bioconjugate was car-
ried out by using epifluorescence microscopy. Internalizing
anti-HER2 single-domain antibody 2Rb17c-C138, which
upon binding to its target cell surface HER2 receptors is
taken up by cells via receptor-mediated endocytosis, was
chosen as delivery vehicle. This feature together with the
smaller format of this antibody relative to full-length anti-
HER2 IgG Thiomab LC-V205C, makes this antibody an ideal
candidate for cell-specific (in this case HER2 +), antibody-
mediated delivery of drugs and therapeutic ONs. 2Rb17c-
C138-Cy3-3’-ss25-mer DNA-antibody bioconjugate probe
with a Cy3 fluorophore attached to the 3’-end of a ss25-mer
ON was prepared (Figure S59). SKBR3 cells were incubated
with this bioconjugate or controls, fixed and imaged (see
epifluorescence microscopy imaging experiments in the SI).
Obtained images demonstrate that Cy3-labelled DNA ON
was localized inside SKBR3 cells only when formulated and
delivered as an ON-antibody conjugate (Figure 5c) and not
detected when cells were incubated with “naked” Cy3-ON
without the antibody vehicle (Figure 5 c). A control experi-
ment in which HER2 receptors were blocked with full-length
anti-HER2 IgG antibody Trastuzumab resulted in 75%
decrease of the Cy3-ON signal (Figure S64) which was
localized mainly on the cell surface presumably as a result
of competition for HER2 receptor binding between 2Rb17c-
C138-Cy3-3’-ss25-mer and Trastuzumab. Additional evidence
was obtained from an imaging experiment in which the same
nanobody directly modified with a fluorophore dye was used.
Conjugate 2Rb17c-C138-C5-AF488 was prepared by modify-
ing the cysteine residue of the nanobody with AF-488-C5-
maleimide under standard conditions (Figure S65). A similar
intracellular localization pattern to 2Rb17c-C138-Cy3-3’-
ss25-mer was observed with 2Rb17c-C138-C5-AF488 conju-
gate (Figure S66). The results provided by super-resolution
and fluorescence microscopy imaging experiments support
the potential of the developed DNA-antibody bioconjugation
platform to be applied for targeted antibody-mediated
delivery of therapeutic ONs.
Conclusion
We have developed an improved protocol for the
bioconjugation of DNA ONs to proteins and antibodies, and
an optimized method for the LC-MS characterization of
prepared bioconjugates. By using easy-to-prepare BA-PFP
reagent 2, various types of ss- or ds-amino-modified DNA
ONs can be labelled with a BA moiety. Prepared BA-
modified ONs are then conjugated to proteins and antibodies
through cysteine selective thiol-Michael addition reactions.
By conjugating different types of DNA ONs to a wide range
of proteins and antibodies, we demonstrate the generality and
versatility of our DNA-protein bioconjugation platform that
gives site-specific and homogenous DNA-protein conjugates.
Importantly, bioconjugates prepared by this method are
stable in the presence of human plasma, which makes them
useful for various in vitro applications, including imaging,
nanofabrication, biosensing or immunological detection
methods[6a] and suitable for in vivo bioassays and potentially
for therapeutic applications.[13] All these features (confirmed
by side-by-side comparative experiments) make our BA-
based DNA-antibody bioconjugation platform superior to the
most popular approaches utilizing maleimides. As an exam-
ple, we have shown that DNA-antibody probes 2Rb17c-C138-
ss11-mer and Thiomab LC-V205C-ss11-mer prepared by our
method can be used to image HER2 receptors on the surface
of HER2 + SKBR3 breast cancer cells by means of DNA-
PAINT super-resolution microscopy.[12, 39] Such studies could
open up the door for development of improved diagnostic
methods for the quantification of expression levels of HER2
or other receptors in breast and other types of cancer by
adapting the method for the quantitative point accumulation
in nanoscale topography (qPAINT).[41] In addition, fluores-
cent DNA-antibody bioconjugate 2Rb17c-C138-Cy3-3’-ss25-
mer was used as a probe in epifluorescence microscopy
imaging experiments to investigate HER2 receptor-mediated
internalization of this DNA-antibody construct in SKBR3
cancer cells. Images obtained from these experiments clearly
showed intracellular localization of 2Rb17c-C138-Cy3-3’-
ss25-mer. The results of this work support the potential of
the developed bioconjugation platform for therapeutic appli-
cations by using antibodies as delivery vehicles for therapeu-
tic ONs. Further studies and developments towards strategies
for more efficient cancer therapies by constructing tumor-
targeting nanostructures or various types of NA-antibody
bioconjugates for targeted delivery of therapeutic ONs are
underway in our laboratories.
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J. Konč, L. Brown, D. R. Whiten, Y. Zuo,
P. Ravn, D. Klenerman,
G. J. L. Bernardes* &&&&—&&&&
A Platform for Site-Specific DNA-
Antibody Bioconjugation by Using
Benzoylacrylic-Labelled Oligonucleotides
BA-PFP is a simple and practical reagent
that enables preparation of a range of
diverse site-specific, homogenous DNA-
protein/antibody bioconjugates under
mild conditions. The generated con-
structs can be conveniently characterized
by an optimized LC-MS method and uti-
lized as probes for cell imaging using
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